Overview

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)

Status:
RECRUITING

Trial end date:
2027-07-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.

Phase:

PHASE3

Details

Lead Sponsor:

Incyte Corporation